DAVITA INC（DVA）の決算・業績分析
DAVITA INCの2025年有価証券報告書をAI分析。売上高$13.6B(+6.5%)。営業利益$2.0B。Health Care。
目次
DAVITA INCの2025年度 業績サマリー
DAVITA INC（証券コード: DVA）の2025年度決算・業績分析。売上高は$13.6B（前年比+6.5%）。営業利益は$2.0B（前年比-2.2%）。純利益は$747M（前年比-20.2%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
DAVITA INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Net income declined 42.7% YoY to $560M (XBRL), driven by a 25.5% YoY drop in operating income to $1.3B (XBRL).
- Free cash flow (FCF) remained strong at $961M (XBRL), despite a 5.2% CapEx intensity (XBRL).
- Share repurchases totaled $802M (XBRL), with no dividends paid, reflecting a focus on shareholder returns.
- Debt-to-equity ratio rose to 13.40x (XBRL), signaling increased leverage despite a healthy current ratio of 1.19x (XBRL).
DAVITA INCの売上高変化の要因
- •Total revenue for FY2024 was $11.6B, a -0.1% YoY decline (XBRL). The 5-year CAGR for revenue is +2.5% (XBRL), but FY2024 growth was flat compared to FY2023. Segment-specific revenue data is not available in the XBRL or 10-K (N/A). The 10-K notes potential drivers of revenue stagnation include supply chain challenges, competitive pressures, and payment rate adjustments (10-K).
DAVITA INCの営業利益変化の要因
- •Operating income fell 25.5% YoY to $1.3B (XBRL), with operating margin at 11.5% (XBRL). Net income dropped 42.7% YoY to $560M (XBRL), with net margin at 4.8% (XBRL). The decline in profitability may be attributed to cost of sales pressures, supply chain disruptions, and competitive dynamics (10-K). EBITDA grew 17.8% YoY to $2.1B (XBRL), indicating resilience in core operations.
DAVITA INCの事業リスクと対応
External factors affecting ESKD patient population growth and treatment volumes (10-K).
Complex regulatory environment and potential legislative changes impacting reimbursement (10-K).
Legal risks from lawsuits, audits, and compliance issues (10-K).
Challenges in implementing integrated kidney care and value-based care strategies (10-K).
Labor cost increases and difficulties retaining skilled clinical personnel (10-K).
DAVITA INCの今後の見通し・業績予想
DAVITA INCの事業内容
DaVita Inc. (DVA) operates as a leading provider of dialysis and related kidney care services in the U.S. and internationally, treating patients with end-stage renal disease (ESRD) and chronic kidney disease. Its business model generates revenue through dialysis treatments, integrated kidney care (IKC) services, and administrative support for international operations. Key segments include U.S. dialysis, international dialysis, U.S. IKC, and ancillary services. Competitive advantages include a patient-centric care model, leadership in quality programs, and established relationships with nephrologists and payors. No significant customer concentration is reported (10-K).
DAVITA INCのAI業績分析レポート（2024年度）
DaVita Inc. (DVA) FY2024 Annual Report Analysis
Highlights
Business Overview
DaVita Inc. operates as a leading provider of dialysis and related kidney care services in the U.S. and internationally, treating patients with end-stage renal disease (ESRD) and chronic kidney disease. Its business model generates revenue through dialysis treatments, integrated kidney care (IKC) services, and administrative support for international operations. Key segments include U.S. dialysis, international dialysis, U.S. IKC, and ancillary services. Competitive advantages include a patient-centric care model, leadership in quality programs, and established relationships with nephrologists and payors. No significant customer concentration is reported (10-K).
Revenue Analysis
Total revenue for FY2024 was $11.6B, a -0.1% YoY decline (XBRL). The 5-year CAGR for revenue is +2.5% (XBRL), but FY2024 growth was flat compared to FY2023. Segment-specific revenue data is not available in the XBRL or 10-K (N/A). The 10-K notes potential drivers of revenue stagnation include supply chain challenges, competitive pressures, and payment rate adjustments (10-K).
Profitability Analysis
Operating income fell 25.5% YoY to $1.3B (XBRL), with operating margin at 11.5% (XBRL). Net income dropped 42.7% YoY to $560M (XBRL), with net margin at 4.8% (XBRL). The decline in profitability may be attributed to cost of sales pressures, supply chain disruptions, and competitive dynamics (10-K). EBITDA grew 17.8% YoY to $2.1B (XBRL), indicating resilience in core operations.
Balance Sheet Analysis
The company’s equity ratio is 6.2% (XBRL), with a debt-to-equity ratio of 13.40x (XBRL), reflecting high leverage. Total cash is $380M (XBRL), and the current ratio is 1.19x (XBRL), suggesting adequate short-term liquidity. Total assets declined slightly from FY2020 to FY2024, remaining stable at $16.9B (XBRL). Total equity dropped from $2.1B in FY2020 to $121M in FY2025 (XBRL).
Cash Flow Analysis
Operating cash flow was $1.6B (XBRL), with free cash flow of $961M (XBRL) after $603M in CapEx (XBRL). No dividends were paid, but $802M was allocated to share repurchases (XBRL). Investing cash flow was -$630M (XBRL), primarily from CapEx. Financing cash flow was -$1.1B (XBRL), driven by repurchases and debt management.
Working Capital Analysis
The cash conversion cycle (CCC) was 51 days (XBRL), with receivables at 62 days, inventory at 4 days, and payables at 16 days (XBRL).
Risks
Outlook
Management highlights ongoing risks from supply chain disruptions, competitive pressures, and payment rate changes (10-K). Strategic initiatives like integrated kidney care and value-based care are expected to shape future results, though no specific financial guidance is provided (10-K).
Health Careの企業一覧
DAVITA INCと同じ「Health Care」セクターの企業